Search Results 151-160 of 18964 for prostate cancer
A new study at Mayo Clinic is using genomic sequencing to develop customized treatments for men with castration-resistant prostate cancer, a progressive and ...
Mayo Gets FDA Approval for New Imaging Agent for Recurrent Prostate Cancer: Radiology · More videos on YouTube · Thank a researcher today · About Mayo Clinic.
... (cancer that has already spread) castration-resistant prostate cancer (prostate cancer that cannot be treated by surgery or medicines that lower testosterone).
Unfortunately, most men in this situation will go on to develop metastatic castration-resistant prostate cancer (mCRPC) and require secondary systemic therapy.
Mayo Clinic specialists perform transperineal biopsy, which helps to accurately diagnose prostate cancer in patients with lesions or past complications and ...
The purpose of this study is to collect prostate surgical samples from metastatic patients to establish xenograft tumor lines for future testing of potential ...
The primary hypotheses are that the TULSA-Procedure is safe and effective treatment of intermediate grade prostate cancer over 2 years. The primary endpoint ...
... prostate cancer. As with other types of prostate laser surgery, HoLEP can offer faster recovery and symptom relief compared with traditional prostate surgery.
About this study. The purpose of this study is to collect blood and urine samples from men already diagnosed with advanced prostate cancer.
Request Appointment · Mayo Gets FDA Approval for New Imaging Agent for Recurrent Prostate Cancer: Urology.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Their crucial work saves lives every day. Let Mayo Clinic researchers know they’re appreciated with a quick message.